

# Multi-Omics Signatures of Alcohol Use Disorder in the Dorsal and Ventral Striatum

Running title: Multi-Omics Signatures of Alcohol Use Disorder

Lea Zillich<sup>1</sup> (MSc), Eric Poisel<sup>1</sup> (MSc), Josef Frank<sup>1</sup> (PhD), Jerome C. Foo<sup>1</sup> (PhD), Marion M. Friske<sup>2</sup> (MSc), Fabian Streit<sup>1</sup> (PhD), Lea Sirignano<sup>1</sup> (MSc), Stefanie Heilmann-Heimbach<sup>3</sup> (PhD), André Heimbach<sup>3</sup> (PhD), Per Hoffmann<sup>3,4</sup> (PhD), Franziska Degenhardt<sup>5</sup> (MD), Anita C. Hansson<sup>2</sup> (PhD), Georgy Bakalkin<sup>6</sup> (PhD), Markus M. Nöthen<sup>3</sup> (MD), Marcella Rietschel<sup>1#</sup> (MD), Rainer Spanagel<sup>2#</sup> (PhD), Stephanie H. Witt<sup>1,7#</sup> (PhD)

<sup>1</sup> Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

<sup>2</sup> Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

<sup>3</sup> Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany

<sup>4</sup> Department of Biomedicine, University of Basel, Basel, 4003, Switzerland

<sup>5</sup> Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

<sup>6</sup> Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

<sup>7</sup> Center for Innovative Psychiatric and Psychotherapeutic Research, Biobank, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

#contributed equally

corresponding author:

Prof. Dr. Rainer Spanagel  
Central Institute of Mental Health  
Institute of Psychopharmacology  
J5  
68159 Mannheim  
Germany  
Phone: +49 621 1703 6251  
Fax: +49 621 1703 6255

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
E-Mail: [Rainer.Spanagel@zi-mannheim.de](mailto:Rainer.Spanagel@zi-mannheim.de)

## 1 Abstract

2 Alcohol Use Disorder (AUD) is a major contributor to global mortality and morbidity.  
3 Postmortem human brain tissue enables the investigation of molecular mechanisms of AUD  
4 in the neurocircuitry of addiction. We aimed to identify differentially expressed (DE) genes in  
5 the ventral and dorsal striatum between individuals with AUD and controls, and to integrate  
6 the results with findings from genome- and epigenome-wide association studies  
7 (GWAS/EWAS) to identify functionally relevant molecular mechanisms of AUD. DNA-  
8 methylation and gene expression (RNA-seq) data was generated from postmortem brain  
9 samples of 48 individuals with AUD and 51 controls from the ventral striatum (VS) and the  
10 dorsal striatal regions caudate nucleus (CN) and putamen (PUT). We identified DE genes  
11 using DESeq2, performed gene-set enrichment analysis (GSEA), and tested enrichment of  
12 DE genes in results of GWASs using MAGMA. Weighted correlation network analysis  
13 (WGCNA) was performed for DNA-methylation and gene expression data and gene overlap  
14 was tested. Differential gene expression was observed in the dorsal (FDR<0.05), but not the  
15 ventral striatum of AUD cases. In the VS, DE genes at FDR<0.25 were overrepresented in a  
16 recent GWAS of problematic alcohol use. The *ARHGEF15* gene was upregulated in all three  
17 brain regions. GSEA in CN and VS pointed towards cell-structure associated GO-terms and  
18 in PUT towards immune pathways. The WGCNA modules most strongly associated with AUD  
19 showed strong enrichment for immune response and inflammation pathways. Our integrated  
20 analysis of multi-omics data sets provides further evidence for the importance of immune-and  
21 inflammation-related processes in AUD.

## 22 Introduction

23 Alcohol Use Disorder (AUD) is a major contributor to the global disease burden, with a  
24 prevalence of ~17% among 12-month alcohol users in the US<sup>1, 2</sup> and an estimated heritability  
25 of 49%<sup>3</sup>. Knowledge about the molecular mechanisms can foster understanding of causes and  
26 promote prevention. Recent genome-wide association studies (GWASs) have identified 29  
27 genetic loci associated with Problematic Alcohol Use (PAU), a proxy of AUD<sup>4</sup>. While GWASs  
28 identify increasing numbers of disease-associated loci, the functional interpretation of many  
29 of these findings remains inconclusive. Analyzing the transcriptome can extend the  
30 understanding of the molecular mechanisms underlying AUD, by identifying associated gene  
31 expression patterns. Findings can in turn be integrated with results from GWASs and  
32 epigenome-wide association studies (EWASs) to identify the pathomechanisms underlying  
33 disease.

34 Processes in the central nervous system are considered to play a major role in the etiology of  
35 addiction, and the transition from chronic alcohol consumption to AUD<sup>5</sup>. Therefore, it is of  
36 particular interest to examine molecular changes associated with addiction in brain tissue. So  
37 far, only few studies have been conducted in postmortem human brain tissue to identify  
38 transcriptional changes associated with AUD<sup>6-8</sup>. These studies mainly focused on the  
39 prefrontal cortex (PFC) one important part of the neurocircuitry of addiction<sup>9, 10</sup>. The first  
40 transcriptome-wide study in the PFC found DE genes implicated in neuronal processes, such  
41 as myelination, neurogenesis, and neural diseases, as well as cellular processes, such as cell  
42 adhesion and apoptosis<sup>11</sup>. In Brodmann Area 9 downregulation of calcium signaling pathways  
43 has been observed in individuals with AUD compared to controls<sup>12</sup>. In the same study, a  
44 weighted gene co-expression analysis (WGCNA) pointed towards modules associated with  
45 AUD case/control status, which were enriched for nicotine and opioid signaling, as well as  
46 immune processes. Another study in the PFC (Brodmann Area 8) showed that co-expression  
47 networks associated with lifetime alcohol consumption were enriched for GWAS signals of  
48 alcohol dependence<sup>6</sup>.

49 Despite the importance of striatal regions in addiction processes, genome-wide human omics  
50 studies of these brain regions are still missing. The striatum is divided into the ventral striatum  
51 (VS), consisting of the nucleus accumbens and olfactory tubercle; and the dorsal striatum,  
52 comprising the caudate nucleus (CN) and putamen (PUT)<sup>13</sup>. The nucleus accumbens is  
53 involved in mediating motivational processes such as aversion and reward, which play a  
54 significant role in the development and maintenance of substance use disorders (SUD)<sup>13</sup>. In  
55 addition to regulating motor function, the CN and PUT are involved in cognitive processes  
56 relevant for addiction, such as executive functioning and cognitive control, reinforcement  
57 learning and habit formation<sup>14</sup>. Analyses of omics data from striatal regions could complement  
58 the knowledge on global molecular changes in the neurocircuitry of addiction in AUD.

59 In a recent EWAS of AUD in postmortem brain tissue, we identified differentially methylated  
60 CpG-sites and regions in the ventral and dorsal striatum<sup>15</sup>. Previous studies have shown the  
61 utility of integrating epigenetic and transcriptomic data in postmortem brain tissue of SUDs  
62 using weighted correlation network analysis (WGCNA)<sup>16</sup>. WGCNA clusters genes or CpG-  
63 sites into co-expressed or co-methylated modules based on correlation matrices. By relating  
64 modules to each other, WGCNA can be used for data integration, providing more insights than  
65 descriptive overlap. For example, whereas a descriptive comparison of histone H3 lysine 4  
66 trimethylation (H3K4me3) and mRNA expression in individuals with AUD and cocaine use  
67 disorder revealed no consistent overlap between H3K4me3 trimethylation and gene  
68 expression<sup>17</sup>, a network analysis identified overlapping modules pointing towards co-  
69 expressed genes associated with H3K4me3 trimethylation<sup>6</sup>. Modules associated with AUD  
70 were enriched for CNS functions, such as synaptic transmission and regulation of  
71 neurogenesis<sup>6</sup>. WGCNA has also been used for integrating epigenetic and transcriptomic data  
72 and investigating their association with opioid use disorder (OUD) in postmortem human brain,  
73 identifying immune-related transcriptional regulation to be enriched in co-expressed and co-  
74 methylated modules<sup>18</sup>.

75 The aim of the present study was to investigate differential gene expression associated with  
76 AUD status in the ventral and dorsal striatum, relate these to GWAS findings, and to integrate

77 the findings with DNA-methylation data using a network approach (WGCNA) in order to  
78 identify functionally relevant molecular mechanisms in AUD.

## 79 Materials and Methods

### 80 Samples

81 Postmortem human brain tissue from CN, PUT and VS of a total of 48 individuals with AUD  
82 and 51 control individuals (68% male) was obtained from the New South Wales Tissue  
83 Resource Centre at the University of Sydney. The Ethics Committee II of the University of  
84 Heidelberg approved the study (reference number 2021-681). After quality control (QC), the  
85 total sample sizes for each brain region were  $N_{CN} = 71$ ,  $N_{PUT} = 77$  and  $N_{VS} = 63$ . Phenotypic  
86 information was assessed by next-of-kin interviews. Inclusion criteria for this study were:  
87 age > 18 years, Western European Ancestry, no history of severe psychiatric or  
88 neurodevelopmental disorders, or SUDs other than AUD and nicotine use disorder or smoking.  
89 AUD was defined as meeting DSM-IV criteria for alcohol dependence and consuming 80g of  
90 alcohol a day or more (control group: <20g/day). Descriptive information can be found in Table  
91 1 and Supplementary Table S1.

### 92 RNA extraction and -sequencing

93 RNA was extracted from frozen tissue according to the manufacturer's protocol using the  
94 Qiagen RNeasy microKit (Qiagen, Hilden, Germany). The RNA Integrity Number (RIN) of all  
95 samples was determined using a TapeStation 4200 (Agilent, Santa Clara, CA). RIN values of  
96 273 samples were larger than 5.5, for which libraries were prepared using the TruSeq  
97 Stranded Total RNA Library Prep Kit (Illumina, San Diego, CA). RNA sequencing was  
98 performed on the NovaSeq 6000 (Illumina) at the Life & Brain Center in Bonn, Germany with  
99 read lengths of 2x100bp and a sequencing depth of 62.5 M read pairs per sample on average.  
100 Technical replicates were sequenced for all but four samples.

## 101 DNA extraction and Methylation Profiling

102 DNA extraction, methylation profiling, and QC was performed as described in Zillich et al.<sup>15</sup>.  
103 In brief, DNA was extracted using the DNeasy extraction kit (Qiagen, Hilden, Germany); the  
104 Illumina HumanMethylation EPIC BeadChip and the Illumina HiScan array scanning system  
105 (Illumina, San Diego, CA) were used to determine DNA-methylation levels. We used an  
106 updated and customized version of the CPACOR pipeline to extract beta values from raw  
107 intensities<sup>19</sup>. Criteria for the removal of samples and probes can be found in Zillich et al.<sup>15</sup>. In  
108 the present analyses, DNA methylation data was included from all subjects from whom gene  
109 expression data was available after QC.

## 110 Statistical Analyses

111 All analyses apart from QC and read mapping were performed using R version 3.6.<sup>120</sup>. An  
112 overview of the analysis workflow can be found in Figure 1. The Benjamini-Hochberg (FDR)<sup>21</sup>  
113 procedure was used to correct for multiple testing. Differentially expressed genes were  
114 considered statistically significant at FDR<0.05. All downstream analyses were performed  
115 using genes significantly differentially expressed at FDR<0.25.

## 116 Mapping and Quantification

117 Sequencing quality was determined using FastQC<sup>22</sup> and 24 samples (11 cases and 13  
118 controls) were excluded due to insufficient sequencing quality (e.g. strong overrepresentation  
119 of sequences, GC distribution). Raw reads were mapped to the human genome (hg38) using  
120 HISAT2 (v.2.1.0)<sup>23</sup>. Quantification was performed with the featureCounts function of the  
121 Rsubread package (v.2.0.1)<sup>24</sup>, with hg38 annotation.

## 122 Differential Gene Expression Analysis

123 Differential gene expression was determined using DESeq2 (v.1.26.0)<sup>25</sup>. Minimal pre-filtering  
124 was applied, removing genes with normalized counts <10 for more than two samples.

125 Technical replicates were merged prior to differential expression analysis using the  
126 collapseReplicates function as implemented in DESeq2. For the differential gene expression  
127 analysis, we included age, sex, RIN, pH-value of the brain, and postmortem interval (PMI) as  
128 covariates, because of their known influence on gene expression<sup>26-28</sup>. To assess residual bias  
129 after adjustment for covariates, we generated Q-Q plots and calculated genomic inflation  
130 factors (Supplementary Figure 1). We further conducted a variance partition analysis using  
131 the variancePartition() function of the corresponding R package<sup>29</sup>, which confirmed the  
132 covariates. Results of this analysis can be found in Supplementary Figure 2. Results were  
133 filtered for differentially expressed (DE) genes with an absolute log<sub>2</sub> fold change larger than  
134 0.02. Volcano plots displaying up- and downregulation of genes for each brain region are  
135 shown in Supplementary Figure 3.

#### 136 Gene-Set Enrichment Analysis

137 Gene-set enrichment analysis was performed using the R package fgsea (v.1.12.0)<sup>30</sup>, for  
138 which DE genes were ranked according to p-value. Enrichment analysis was performed for  
139 Gene-Ontology (GO) terms<sup>31</sup> and Hallmark gene sets<sup>32</sup> and the results were adjusted using  
140 FDR correction.

#### 141 Cell Type Enrichment Analysis

142 To identify cell type specific expression signatures, we performed cell type enrichment  
143 analysis using DE genes (FDR<0.25) from the three brain regions. As a reference gene set  
144 for brain cell types, we used the “top ranked cell type-enriched genes based on human data”  
145 as provided by McKenzie, Wang<sup>33</sup>. These contain the 1000 most enriched genes in a cell type  
146 and cover astrocytes, endothelial cells, microglia, neurons, and oligodendrocytes. Using the  
147 R package GeneOverlap (v.1.22.0)<sup>34</sup>, we assessed the overlap of AUD-status associated DE  
148 genes with markers from the different cell populations. Results were adjusted for multiple  
149 testing using the Benjamini-Hochberg method as implemented in GeneOverlap.

## 150 Differential Methylation Analysis

151 Effect sizes and p values for CpG sites were used from the EWAS results as presented in the  
152 original publication<sup>15</sup>. In brief, the EWAS model was based on methylation M-values as the  
153 dependent variable and AUD status as the predictor. As covariates, sex, age, postmortem  
154 interval (PMI), pH-value, estimated smoking, standardized neuronal cell count, and the first  
155 ten principal components of the EPIC array internal control probes were included.

## 156 WGCNA

157 Weighted correlation network analyses (WGCNA, v.1.70-3)<sup>16</sup> were performed to identify  
158 modules of co-expressed genes and co-methylated CpG-sites. We assessed the relationship  
159 of these modules with AUD case/control status and tested the overlap between associated  
160 modules. WGCNA clusters the input matrix according to a dynamic tree cutting algorithm,  
161 using a soft power threshold that approximates the criterion of scale-free topology  
162 ( $R_{signed}^2 > 0.80$ ). Resulting soft power thresholds for expression networks were 6 for CN, 5 for  
163 PUT, and 14 for VS; for methylation networks, all power thresholds were 2.

164 To identify methylation networks associated with gene expression, beta values from  
165 normalized intensities of all samples from which gene expression data were available were  
166 filtered for promoter-associated CpG-sites based on the manufacturer's manifest (Illumina,  
167 San Diego, CA). The resulting 105 796 CpG-sites were used as input.

168 For the RNA-seq data, count matrices were normalized using the DESeq2 function  
169 normalizeCounts and variance stability transformation was applied.

170 Networks were constructed using following settings: minimum module size=30,  
171 mergeCutHeight=0.25, maxBlockSize=36 000. In WGCNA, modules are labeled using colors.

172 In the results section modules are labeled according to type of data, brain region, and color  
173 assigned in the analysis, e.g. "e-VS-pink" for module "pink" from the WGCNA analysis of gene  
174 expression data in the ventral striatum. For each module, its eigengene was calculated and  
175 correlated with AUD status. Association of modules with AUD status and covariates is shown  
176 in Supplementary Figure 4. For modules associated with AUD status, we performed



177 enrichment analysis using the GOenrichmentAnalysis function implemented in the WGCNA  
178 package for expression data and the R package missMethyl (v.1.20.4)<sup>35</sup> for methylation  
179 modules. Further, we extracted hub genes of AUD associated WGCNA expression modules  
180 by calculating the product of module membership and gene significance for each gene of a  
181 module. Based on this score, the 10% of highest ranking genes were defined as module hub  
182 genes. To investigate the biological relevance of hub genes, protein-protein interaction  
183 networks were generated using the *Search Tool for the Retrieval of Interacting Genes/Proteins*  
184 (STRING, v.11.5)<sup>36</sup>. Graphical representation of gene networks was restricted to high  
185 confidence interactions (interaction score threshold 0.7).

## 186 Expression and Methylation Data Integration

187 To identify genes both DE and differentially methylated, we analyzed the overlap of DE genes  
188 (FDR<0.25) with the results of an EWAS (p<0.001) in the same sample<sup>15</sup>. We prioritized CpG-  
189 sites based on their functional relevance in gene expression regulation. Thus, promoter-  
190 associated CpG-sites were used in the analysis.

191 At the module level, gene-set overlap tests were performed using the R package GeneOverlap  
192 (v.1.22.0)<sup>34</sup>. Here, Fisher's exact test is used to identify significant overlap. For each brain  
193 region, the overlap of the AUD-associated co-expression and co-methylation modules was  
194 tested.

## 195 GWAS Enrichment Analysis

196 We analyzed enrichment of DE genes with an FDR<0.25, and genes in AUD-associated  
197 WGCNA modules in GWAS summary statistics using Multi-marker Analysis of GenoMic  
198 Annotation (MAGMA, v.1.08b)<sup>37</sup>. We performed GWAS enrichment analysis for several SUDs,  
199 such as alcohol use disorder and problematic alcohol use<sup>4</sup>, cannabis use disorder<sup>38</sup>, and a  
200 recent GWAS comparing individuals with opioid use disorder with unexposed controls<sup>39</sup>.  
201 Bonferroni correction (n=4 tests per gene set) of p values was applied to adjust for multiple  
202 testing.

## 203 Results

### 204 Differential Gene Expression

205 Gene expression analysis of postmortem brain tissue from AUD cases and controls revealed  
206 DE genes at  $FDR < 0.05$  in both dorsal striatal regions. In the caudate nucleus, 49 DE genes  
207 were identified at  $FDR < 0.05$  (39 up- and 10 downregulated). Tubulin Tyrosine Ligase Like 4  
208 (*TTLL4*,  $\log_2FC = 0.11$ ,  $p = 2.3 \times 10^{-8}$ ) and GATA Binding Protein 2 (*GATA2*,  $\log_2FC = -0.27$ ,  
209  $p = 8.6 \times 10^{-7}$ ) were the most significantly upregulated and downregulated genes, respectively.  
210 Top up- and downregulated genes in the putamen were found to be Transcription Elongation  
211 Factor A Like 2 (*TCEAL2*,  $\log_2FC = 0.09$ ,  $p = 5.8 \times 10^{-5}$ ) and Desmin (*DES*,  $\log_2FC = -0.86$ ,  
212  $p = 2.6 \times 10^{-6}$ ), the latter being the only significant gene after correction for multiple testing. Nine  
213 genes were downregulated in both dorsal striatal regions, with *HLA-DOB* having the highest  
214  $\log_2FC$  in both regions. In the ventral striatum, no DE genes were detected at  $FDR < 0.05$ . The  
215 most significant differential gene expression in the ventral striatum was observed for Ankyrin  
216 Repeat And Ubiquitin Domain Containing 1 (*ANKUB1*) which was upregulated in AUD cases  
217 ( $\log_2FC = 1.35$ ,  $p = 5.8 \times 10^{-5}$ ). In the VS of AUD cases Caseinolytic Mitochondrial Matrix  
218 Peptidase Chaperone Subunit B (*CLPB*,  $\log_2FC = -0.11$ ,  $p = 5.2 \times 10^{-6}$ ) was the most significantly  
219 downregulated gene.  
220 None of the DE genes at  $FDR < 0.05$  overlapped between multiple brain regions. Therefore,  
221 the less conservative significance threshold of  $FDR < 0.25$ , which was also used for  
222 downstream analyses, was applied to compare the overlap of DE genes. At  $FDR < 0.25$  the  
223 cardiomyopathy associated 5 (*CMYA5*) gene showed an upregulation in both caudate nucleus  
224 and putamen. *ARHGEF15* (Rho Guanine Nucleotide Exchange Factor 15) was upregulated in  
225 all three brain regions at  $FDR < 0.25$ . The Top 5 DE genes from each brain region are listed in  
226 Table 2; complete summary statistics are listed in Supplementary Table S2 (CN), S3 (PUT),  
227 and S4 (VS). Overlap between DE genes in the different brain regions is shown in Figure 2A.

## 228 Gene-set Enrichment Analysis

229 Pathway analysis using a pre-ranked enrichment analysis revealed significant enrichment of  
230 dorsal striatum DE genes for several GO terms and Hallmark gene-sets. Genes in the CN  
231 were found to be related to cilia- and microtubule-associated GO-terms, while none of the  
232 Hallmark gene-sets was significantly enriched. GO-term and Hallmark gene-set analysis in  
233 PUT samples showed enrichment for immune processes, such as “acute inflammatory  
234 response to antigenic stimuli” ( $p_{\text{FDR}}=0.006$ ) and “adaptive immune response” ( $p_{\text{FDR}}=0.006$ ). In  
235 the VS the most significantly enriched GO-terms were also related to cilia and microtubules,  
236 as well as antigen processing. All GO-terms and Hallmark gene-set with  $\text{FDR} < 0.10$  are listed  
237 in Supplementary Tables S5 (CN), S6 (PUT), and S7 (VS).

## 238 Cell Type Enrichment Analysis

239 In the CN, upregulated DE genes were significantly enriched for astrocytic markers ( $p_{\text{FDR}}$   
240  $=7*10^{-6}$ ), whereas an enrichment for endothelial cell marker genes was detected among  
241 downregulated genes ( $p_{\text{FDR}}=2*10^{-7}$ ). No significant cell-type enrichment of DE genes was  
242 found in the putamen and the ventral striatum. GeneOverlap heatmap visualizations for the  
243 three brain regions are displayed in Supplementary Figure 5.

## 244 WGCNA

### 245 Expression

246 In the CN, 21 modules with a median size of 352 genes (range: 64-7 259) were identified.  
247 Module “e-CN-magenta”, consisting of 328 genes, showed the strongest positive association  
248 with AUD status ( $r=0.42$ ,  $p=2.89*10^{-4}$ ). In the PUT, of the 25 modules (median size 249 genes,  
249 range: 33-5 381) identified, module “e-PUT-black” was most strongly correlated with AUD with  
250 a positive direction of effect ( $r=0.41$ ,  $p=2.31*10^{-4}$ ). For expression data from the ventral  
251 striatum, 16 modules with a median size of 429 genes (range: 35-9 708) were identified;

252 module “e-VS-pink” had the strongest positive association with AUD ( $r=0.41$ ,  $p=0.009$ ).  
253 Interestingly, in a GO-term analysis the three AUD associated modules were all enriched for  
254 immune processes, such as “defense response” and “inflammation response”. Gene network  
255 representation of hub genes in modules “e-CN-magenta”, “e-VS-pink”, and “e-PUT-black”  
256 revealed the signal transducer and activator of transcription 3 (*STAT3*) gene as a conserved  
257 hub node in all three brain regions (Figure 2D-2F). There was also a wide overlap of the genes  
258 in the three modules: 174 (22.54%) were partially shared between all three modules  
259 corresponding to the three brain regions, while another 21.76% were shared between at least  
260 two modules (Figure 2B). A gene network analysis of the 174 shared genes between regions  
261 identified *STAT3*, *TP53*, *ICAM1*, *MYC*, and *NFKBIA* as the top 5 hub nodes of the network. A  
262 visualization of the network is depicted in Figure 3.

## 263 Methylation

264 In the CN, WGCNA resulted in 36 modules with a median size of 346 CpG-sites (range: 66-  
265 41 423). Module “m-CN-red”, consisting of 2 117 CpG-sites, showed the strongest association  
266 with AUD case control status ( $r=-0.27$ ,  $p=0.021$ ). This module was most highly enriched for  
267 the biological processes “cell activation” ( $p=1.52 \times 10^{-5}$ ) and “leukocyte activation” ( $p=2.09 \times 10^{-5}$ ).  
268 In PUT 177 modules were identified (median size=57 CpG-sites, range: 30-42 248). Module  
269 “m-PUT-plum” consisted of 70 CpG-sites and was significantly associated with AUD  
270 case/control status ( $r=-0.29$ ,  $p=0.023$ ) and enriched for the biological processes “positive  
271 regulation of I- $\kappa$ B kinase/NF- $\kappa$ B signaling” ( $p=0.002$ ) and “regulation of I- $\kappa$ B kinase/NF- $\kappa$ B  
272 signaling” ( $p=0.005$ ). WGCNA in the VS methylation data resulted in 85 modules (median  
273 size=178 CpG-sites, range: 35-30 370). The module with the strongest association with AUD  
274 was “m-VS-lavender” ( $r=-0.29$ ,  $p=0.023$ ), which consisted of 117 CpG-sites and was enriched  
275 for the molecular function “natural killer cell lectin-like receptor binding” ( $p=3.43 \times 10^{-4}$ ) and the  
276 biological process “susceptibility to natural killer cell mediated cytotoxicity” ( $p=3.65 \times 10^{-4}$ ). The  
277 top 10 enriched GO-terms for all AUD-associated modules can be found in Supplementary  
278 Tables S8-S10.

## 279 Expression and Methylation Data Integration

280 In the CN, 12 genes showed both differential methylation and differential gene expression. DE  
281 statistics, EWAS summary statistics and functional annotation for these genes are provided in  
282 Supplementary Table S11. No overlap was observed in the VS and PUT. At the module-level,  
283 co-expression module “e-CN-magenta” showed significant overlap with the methylation  
284 modules “m-CN-red” ( $p=0.003$ ) and “m-CN-midnightblue” ( $p=0.014$ ) (Figure 2C), while  
285 expression module “e-CN-purple” did not show significant overlap with the methylation  
286 modules in CN. Of the 3 AUD-associated expression modules in the VS, only “e-VS-salmon”  
287 showed significant overlap with the methylation module “m-VS-turquoise” ( $p=0.003$ ), but not  
288 “m-VS-lavender”. No overlap was observed for gene expression and DNA-methylation in PUT.  
289

## 290 GWAS Enrichment Analysis of DE Genes and WGCNA modules

291 In the VS, but not in the dorsal striatum, we observed enrichment of DE genes in the GWAS  
292 signal of PAU ( $p=0.045$ ). In the putamen DE genes were enriched for GWAS signal from a  
293 study comparing individuals with OUD to unexposed controls ( $p=0.025$ ). None of the DE genes  
294 in any of the brain regions showed enrichment for signals from a GWAS of Cannabis Use  
295 Disorder or AUD.  
296 From the WGCNA modules showing the strongest association with AUD, only module e-VS-  
297 pink showed significant enrichment for GWAS signals of CUD ( $p=0.043$ ). None of the findings  
298 remained statistically significant after multiple testing correction. Results from the respective  
299 analyses are depicted in Supplementary Figure 6 and enrichment  $p$  values as well as the  
300 number of overlapping genes are displayed in Supplementary Table S12.

## 301 Discussion

302 In the present study, we identified DE genes, co-expression networks, and pathways  
303 associated with AUD in the dorsal and ventral striatum. The results were integrated with DNA-  
304 methylation data and results from GWASs of SUDs.

305 We discovered that one gene (*ARHGEF15*) was consistently upregulated in all investigated  
306 brain regions of AUD cases compared to controls. *ARHGEF15* encodes a specific guanine  
307 nucleotide exchange factor for the activation of Ras homolog family member A (RhoA), a  
308 GTPase, which has been linked to higher blood pressure and hypertension over the  
309 Rho/ROCK signaling cascade<sup>40</sup>. It is postulated that the Rho Guanine Nucleotide Exchange  
310 Factor 15 negatively regulates excitatory synapse development by suppressing the synapse-  
311 promoting activity of EPHB2<sup>41</sup>. EPHB2 deficiency has been linked to depression-like behaviors  
312 and memory impairments in animal studies<sup>42</sup>. In line with this, genetic variation within  
313 *ARHGEF15* has been associated with hematocrit, red blood cell count, and hemoglobin  
314 concentration<sup>43</sup>, but also with psychiatric traits, such as neuroticism and worries<sup>44</sup> as well as  
315 bipolar disorder<sup>45</sup>.

316 Among the genes that were downregulated in both dorsal striatal regions, *HLA-DOB* displayed  
317 the highest fold change. HLAs of the Major Histocompatibility Class II are an essential part of  
318 the acquired immune system presenting antigens to T-lymphocytes (for review: Howell, Carter  
319 <sup>46</sup>). The most significantly downregulated gene in the VS is *CLPB*, a mitochondrial chaperone,  
320 which has been associated with progressive brain atrophy<sup>47</sup> and with the cellular response to  
321 alcohol-induced stress<sup>48</sup>. In a recent GWAS, *CLPB* was associated with the amount of alcohol  
322 consumed on a typical day ( $p=9.67 \times 10^{-5}$ ,  $N=116\ 163$ )<sup>49</sup>.

323 DE genes in the ventral striatum were enriched for GWAS signals of PAU, but not AUD. This  
324 could be a result of the larger sample size of the PAU GWAS, but also point towards  
325 differences in genetic variation as responsible for differential expression.

326 Our results from the pathway and network analyses further underline immune-related effects  
327 of chronic alcohol exposure; the pathway and network modules most strongly associated with

328 AUD case-control status were also enriched for immune system and inflammation processes.  
329 This was observed for all three brain regions, and both in expression and methylation data,  
330 providing further evidence for the important role of immune processes in AUD.  
331 Gene networks derived from WGCNA hub genes similarly revealed genes related to  
332 inflammatory processes as strongly connected network nodes. Here, *STAT3* represents a  
333 conserved network hub node in all three brain regions. *STAT3* is a member of the JAK/STAT  
334 pathway and acts as a transcription factor upon activation by cytokines, hormones and growth  
335 factors<sup>50</sup>. Interestingly, a recent study assessing expression signatures of alcohol withdrawal  
336 in rats discovered a very similar gene network in the hippocampus with *STAT3* as a hub node  
337 surrounded by a network of downstream targets<sup>51</sup>. The authors also discovered increased  
338 levels of *STAT3* and its neuroinflammation-related target genes in postmortem brain tissue of  
339 subjects with AUD. Activation of the *STAT3* gene network was found to be primarily restricted  
340 to astrocytes. This supports the results of the cell type enrichment analyses, where enrichment  
341 of astrocytic expression signatures was detected for upregulated DE genes in the CN.  
342 These results strongly reflect the well-described effect of chronic alcohol exposure on different  
343 aspects of the innate and acquired immune systems<sup>52</sup>. Chronic alcohol exposure accelerates  
344 the inflammatory response and reduces anti-inflammatory cytokines<sup>52</sup>. An activated immune  
345 response in response to chronic alcohol exposure has been shown on the cell level<sup>53</sup>, as well  
346 as on the transcription<sup>53</sup>, and protein levels<sup>54, 55</sup>. In a previous EWAS, we found strong  
347 enrichment of immune processes in differentially methylated CpG-sites associated with  
348 alcohol withdrawal<sup>56</sup>. Neuroinflammation has been repeatedly associated with AUD and both  
349 the glutamate excitotoxicity and the production of acetaldehyde, key processes in AUD  
350 metabolism, have been suggested to produce an inflammatory response in the brain<sup>57</sup>. On a  
351 phenotypic level, there is also widespread overlap between symptoms of inflammation and of  
352 SUDs, such as anhedonia, depression, and decreased cognitive functioning<sup>58</sup>. In addition, in  
353 candidate gene studies in postmortem human PFC, hippocampus, and orbitofrontal cortex,  
354 increased mRNA levels of *HMGB1*, which encodes a proinflammatory cytokine and toll-like  
355 receptor genes have been associated with alcohol consumption in AUD cases, providing



356 evidence for chronic neuroinflammation in response to alcohol<sup>59-61</sup>. Notably, there is an overlap  
357 of findings not only on the single-gene level but also on the level of pathways and  
358 networks/modules. This overlap underlines that alcohol consumption has common biological  
359 effects in different brain regions, i.e., most prominently, effects on immune and inflammation  
360 processes.

361 Several limitations apply to our study. First, we cannot distinguish between effects being a  
362 consequence of chronic alcohol consumption or addiction. Second, although we corrected for  
363 PMI, which can influence tissue quality as a confounding factor, it cannot be ruled out that  
364 other characteristics not easily accounted for, such as cause of death, or blood alcohol level  
365 for which the majority of individuals have missing data, influenced gene expression. Third,  
366 although the sample size is comparatively large for postmortem brain studies in the addiction  
367 field, the small number of differentially expressed genes is likely attributable to limited power.  
368 Lastly, analyzing bulk tissue does not adequately reflect the diversity of cell types across  
369 different brain regions and future studies on single-cell level are needed to investigate cell-  
370 type specific transcriptional changes associated with AUD.

371 It has to be noted that besides DNA methylation, epigenetic mechanisms such as histone and  
372 chromatin modifications, or microRNA expression profiles can influence gene expression and  
373 are especially important in addiction research<sup>62</sup>. Future studies should therefore expand the  
374 epigenetic profiling of AUD to include these mechanisms.

375 In summary, the present study provides further evidence from multi-omics data sets for the  
376 importance of immune-and inflammation-related processes in AUD. Notably, drugs that  
377 reduce neuroinflammation to reduce drinking, such as phosphodiesterases, may be promising  
378 approaches for novel treatment options for AUD. Recently published randomized controlled  
379 trials suggest that a phosphodiesterase inhibitor reduces heavy drinking whereas an antibiotic  
380 compound was not effective<sup>63, 64</sup>. A deeper understanding of the underlying mechanisms will  
381 enhance the discovery of drug targets and drive forward the development of precision  
382 medicine within in this field.



## 383 Acknowledgments

384 The study was supported by the German Federal Ministry of Education and Research (BMBF),  
385 “A systems-medicine approach towards distinct and shared resilience and pathological  
386 mechanisms of substance use disorders” (01ZX01909), “Towards Targeted Oxytocin  
387 Treatment in Alcohol Addiction” (031L0190). ERA-NET: Psi-Alc (01EW1908), and the  
388 Deutsche Forschungsgemeinschaft (DFG) – Project-ID 402170461 – TRR 265<sup>65</sup>.

389 We thank Elisabeth Röbel and Claudia Schäfer-Arnold for technical assistance.

390 Tissues were received from the New South Wales Brain Tissue Resource Centre at the  
391 University of Sydney which is supported by the University of Sydney. Research reported in  
392 this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of  
393 the National Institutes of Health under Award Number R28AA012725. The content is solely  
394 the responsibility of the authors and does not represent the official views of the National  
395 Institutes of Health.

## 396 Conflict of Interest

397 The authors have nothing to disclose.

## 398 Supplementary Information

399 Supplementary information is available at MP’s website.

## 400 Data and Code Availability

401 Raw data and analysis code are available from the corresponding author upon reasonable  
402 request.

## References

1. World Health Organization. *Global status report on alcohol and health 2018*. World Health Organization 2019.
2. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ *et al*. Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry* 2017; **74**(9): 911-923.
3. Verhulst B, Neale MC, Kendler KS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. *Psychological medicine* 2015; **45**(5): 1061.
4. Zhou H, Sealock JM, Sanchez-Roige S, Clarke T-K, Levey DF, Cheng Z *et al*. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. *Nature Neuroscience* 2020; **23**(7): 809-818.
5. Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. *New England Journal of Medicine* 2016; **374**(4): 363-371.
6. Farris SP, Arasappan D, Hunnicke-Smith S, Harris RA, Mayfield RD. Transcriptome organization for chronic alcohol abuse in human brain. *Mol Psychiatry* 2015; **20**(11): 1438-1447.
7. Ponomarev I, Wang S, Zhang L, Harris RA, Mayfield RD. Gene coexpression networks in human brain identify epigenetic modifications in alcohol dependence. *J Neurosci* 2012; **32**(5): 1884-1897.
8. Liu J, Lewohl JM, Dodd PR, Randall PK, Harris RA, Mayfield RD. Gene expression profiling of individual cases reveals consistent transcriptional changes in alcoholic human brain. *J Neurochem* 2004; **90**(5): 1050-1058.
9. Koob GF, Volkow ND. Neurocircuitry of Addiction. *Neuropsychopharmacology* 2010; **35**(1): 217-238.
10. Noori HR, Spanagel R, Hansson AC. Neurocircuitry for modeling drug effects. *Addict Biol* 2012; **17**(5): 827-864.
11. Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK *et al*. Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. *Neuropsychopharmacology* 2006; **31**(7): 1574-1582.
12. Kapoor M, Wang JC, Farris SP, Liu Y, McClintick J, Gupta I *et al*. Analysis of whole genome-transcriptomic organization in brain to identify genes associated with alcoholism. *Transl Psychiatry* 2019; **9**(1): 89.
13. Volkow ND, Morales M. The Brain on Drugs: From Reward to Addiction. *Cell* 2015; **162**(4): 712-725.

14. Galandra C, Basso G, Cappa S, Canessa N. The alcoholic brain: neural bases of impaired reward-based decision-making in alcohol use disorders. *Neurol Sci* 2018; **39**(3): 423-435.
15. Zillich L, Frank J, Streit F, Friske MM, Foo JC, Sirignano L *et al*. Epigenome-wide association study of alcohol use disorder in five brain regions. *Neuropsychopharmacology* 2022; **47**(4): 832-839.
16. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC bioinformatics* 2008; **9**(1): 559.
17. Zhou Z, Yuan Q, Mash DC, Goldman D. Substance-specific and shared transcription and epigenetic changes in the human hippocampus chronically exposed to cocaine and alcohol. *Proc Natl Acad Sci U S A* 2011; **108**(16): 6626-6631.
18. Liu A, Dai Y, Mendez EF, Hu R, Fries GR, Najera KE *et al*. Genome-Wide Correlation of DNA Methylation and Gene Expression in Postmortem Brain Tissues of Opioid Use Disorder Patients. *International Journal of Neuropsychopharmacology* 2021.
19. Lehne B, Drong AW, Loh M, Zhang W, Scott WR, Tan ST *et al*. A coherent approach for analysis of the Illumina HumanMethylation450 BeadChip improves data quality and performance in epigenome-wide association studies. *Genome Biol* 2015; **16**(1): 37.
20. Team RC. R: A language and environment for statistical computing. 2013.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: series B* 1995; **57**(1): 289-300.
22. Andrews S. FastQC: A quality control tool for high throughput sequencing data. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>, 2010.
23. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nature Biotechnology* 2019; **37**(8): 907-915.
24. Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Research* 2019; **47**(8): e47-e47.
25. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* 2014; **15**(12): 550.
26. Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw J-J, Seilhean D *et al*. Effects of Antemortem and Postmortem Variables on Human Brain mRNA Quality: A BrainNet Europe Study. *Journal of Neuropathology & Experimental Neurology* 2010; **69**(1): 70-81.
27. Trabzuni D, Ryten M, Walker R, Smith C, Imran S, Ramasamy A *et al*. Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. *Journal of Neurochemistry* 2011; **119**(2): 275-282.

28. Birdsill AC, Walker DG, Lue L, Sue LI, Beach TG. Postmortem interval effect on RNA and gene expression in human brain tissue. *Cell and Tissue Banking* 2011; **12**(4): 311-318.
29. Hoffman GE, Schadt EE. variancePartition: interpreting drivers of variation in complex gene expression studies. *BMC Bioinformatics* 2016; **17**(1): 483.
30. Sergushichev AA. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. *bioRxiv* 2016: 060012.
31. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM *et al.* Gene Ontology: tool for the unification of biology. *Nature Genetics* 2000; **25**(1): 25-29.
32. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov Jill P, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Systems* 2015; **1**(6): 417-425.
33. McKenzie AT, Wang M, Hauberg ME, Fullard JF, Kozlenkov A, Keenan A *et al.* Brain Cell Type Specific Gene Expression and Co-expression Network Architectures. *Scientific reports* 2018; **8**(1): 8868.
34. Shen L. GeneOverlap: Test and visualize gene overlaps. R package version 1.28.0, 2021.
35. Phipson B, Maksimovic J, Oshlack A. missMethyl: an R package for analyzing data from Illumina's HumanMethylation450 platform. *Bioinformatics* 2016; **32**(2): 286-288.
36. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S *et al.* The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Research* 2021; **49**(D1): D605-D612.
37. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLOS Computational Biology* 2015; **11**(4): e1004219.
38. Johnson EC, Demontis D, Thorgeirsson TE, Walters RK, Polimanti R, Hatoum AS *et al.* A large-scale genome-wide association study meta-analysis of cannabis use disorder. *The Lancet Psychiatry* 2020; **7**(12): 1032-1045.
39. Polimanti R, Walters RK, Johnson EC, McClintick JN, Adkins AE, Adkins DE *et al.* Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. *Mol Psychiatry* 2020; **25**(8): 1673-1687.
40. Wirth A. Rho kinase and hypertension. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 2010; **1802**(12): 1276-1284.
41. Margolis SS, Salogiannis J, Lipton DM, Mandel-Brehm C, Wills ZP, Mardinly AR *et al.* EphB-Mediated Degradation of the RhoA GEF Ephexin5 Relieves a Developmental Brake on Excitatory Synapse Formation. *Cell* 2010; **143**(3): 442-455.
42. Zhen L, Shao T, Luria V, Li G, Li Z, Xu Y *et al.* EphB2 Deficiency Induces Depression-Like Behaviors and Memory Impairment: Involvement of NMDA 2B Receptor Dependent Signaling. *Frontiers in Pharmacology* 2018; **9**(862).

43. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell* 2016; **167**(5): 1415-1429.e1419.
44. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, Bryois J *et al.* Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. *Nature Genetics* 2018; **50**(7): 920-927.
45. Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N *et al.* A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder. *Mol Psychiatry* 2018; **23**(3): 639-647.
46. Howell WM, Carter V, Clark B. The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques. *Journal of clinical pathology* 2010; **63**(5): 387-390.
47. Saunders C, Smith L, Wibrand F, Ravn K, Bross P, Thiffault I *et al.* CLPB Variants Associated with Autosomal-Recessive Mitochondrial Disorder with Cataract, Neutropenia, Epilepsy, and Methylglutaconic Aciduria. *The American Journal of Human Genetics* 2015; **96**(2): 258-265.
48. Tóth ME, Vigh L, Sántha M. Alcohol stress, membranes, and chaperones. *Cell Stress and Chaperones* 2014; **19**(3): 299-309.
49. Watanabe K, Stringer S, Frei O, Umičević Mirkov M, de Leeuw C, Polderman TJC *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nat Genet* 2019; **51**(9): 1339-1348.
50. Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaba Z, Fafouri A *et al.* The role of JAK-STAT signaling within the CNS. *JAKSTAT* 2013; **2**(1): e22925-e22925.
51. Chen W-Y, Chen H, Hamada K, Gatta E, Chen Y, Zhang H *et al.* Transcriptomics identifies STAT3 as a key regulator of hippocampal gene expression and anhedonia during withdrawal from chronic alcohol exposure. *Translational Psychiatry* 2021; **11**(1): 298.
52. Szabo G, Saha B. Alcohol's Effect on Host Defense. *Alcohol research : current reviews* 2015; **37**(2): 159-170.
53. McClintick JN, Tischfield JA, Deng L, Kapoor M, Xuei X, Edenberg HJ. Ethanol activates immune response in lymphoblastoid cells. *Alcohol* 2019; **79**: 81-91.
54. Donnadieu-Rigole H, Mura T, Portales P, Duroux-Richard I, Bouthier M, Eliaou JF *et al.* Effects of alcohol withdrawal on monocyte subset defects in chronic alcohol users. *Journal of leukocyte biology* 2016; **100**(5): 1191-1199.
55. Yen CH, Ho PS, Yeh YW, Liang CS, Kuo SC, Huang CC *et al.* Differential cytokine levels between early withdrawal and remission states in patients with alcohol dependence. *Psychoneuroendocrinology* 2017; **76**: 183-191.
56. Witt SH, Frank J, Frischknecht U, Treutlein J, Streit F, Foo JC *et al.* Acute alcohol withdrawal and recovery in men lead to profound changes in DNA methylation profiles: a longitudinal clinical study. *Addiction (Abingdon, England)* 2020; **115**(11): 2034-2044.

57. de Timary P, Stärkel P, Delzenne NM, Leclercq S. A role for the peripheral immune system in the development of alcohol use disorders? *Neuropharmacology* 2017; **122**: 148-160.
58. Crews FT, Lawrimore CJ, Walter TJ, Coleman LG. The role of neuroimmune signaling in alcoholism. *Neuropharmacology* 2017; **122**: 56-73.
59. Crews FT, Qin L, Sheedy D, Vetreno RP, Zou J. High mobility group box 1/Toll-like receptor danger signaling increases brain neuroimmune activation in alcohol dependence. *Biol Psychiatry* 2013; **73**(7): 602-612.
60. Coleman LG, Jr., Zou J, Crews FT. Microglial-derived miRNA let-7 and HMGB1 contribute to ethanol-induced neurotoxicity via TLR7. *J Neuroinflammation* 2017; **14**(1): 22.
61. Vetreno RP, Qin L, Coleman Jr LG, Crews FT. Increased Toll-like Receptor-MyD88-NFκB-Proinflammatory neuroimmune signaling in the orbitofrontal cortex of human alcohol use disorder. *Alcoholism: Clinical and Experimental Research* 2021; **00**: 1-15.
62. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. *Nature Reviews Neuroscience* 2011; **12**(11): 623-637.
63. Grodin EN, Bujarski S, Towns B, Burnette E, Nieto S, Lim A *et al.* Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. *Translational Psychiatry* 2021; **11**(1): 355.
64. Petrakis IL, Ralevski E, Gueorguieva R, Sloan ME, Devine L, Yoon G *et al.* Targeting neuroinflammation with minocycline in heavy drinkers. *Psychopharmacology (Berl)* 2019; **236**(10): 3013-3021.
65. Heinz A, Kiefer F, Smolka MN, Endrass T, Beste C, Beck A *et al.* Addiction Research Consortium: Losing and regaining control over drug intake (ReCoDe)—From trajectories to mechanisms and interventions. *Addict Biol* 2020; **25**(2): e12866.

## Figure Legends

Figure 1. Analysis workflow of the present study.

Figure 2. Venn Diagrams of gene overlap of A) DE genes at FDR < 0.25 in caudate nucleus (CN), putamen (PUT), and ventral striatum (VS), B) genes forming WGCNA expression-modules showing the strongest association with AUD status for CN, PUT, and VS, C) genes forming WGCNA expression-module “e-CN-magenta” and those forming the methylation-modules “m-CN-red” and “m-CN-midnightblue”. Network plots depicting the WGCNA gene expression modules showing the strongest association with AUD: D) module magenta from caudate nucleus, E) module black from putamen and F) module pink from ventral striatum.

Figure 3. Network plot of genes, co-expressed between the WGCNA modules e-CN-magenta, e-PUT-black and e-VS-pink.



## Tables

Table 1.

*Descriptive statistics of demographic data.*

Characteristic	Cases	Controls	<i>p</i>
N	48	51	
Age, years	55.58 (10.62)	57 (10.64)	0.51
Sex (M/F)	31/17	37/14	
pH-value	6.53 (0.26)	6.65 (0.25)	0.026*
PMI (hours)	37.07 (15.79)	30.7 (15.57)	0.047*
Blood Alcohol level (N)	7	0	
Blood Alcohol Level (g/100ml)	0.21 (0.21)		
Smoking (yes/%)	32 (66.7%)	12 (23.5%)	<0.001*
Samples per Brain Region			
Caudate Nucleus	36	37	
Putamen	35	42	
Ventral Striatum	31	32	

*Data are presented as count (n/n; n (%)) or mean ( $\pm$ SD), PMI: post-mortem interval, pH: pH-value of the brain, *p*: *p*-value of *t*-Test/Chi-squared test comparing cases and controls.*

*\*significant difference between cases and controls*



Table 2.

Entrez Gene ID	Gene Name	baseMean	log2(FC)	lfcSE	Stat	P-Value	FDR
Caudate Nucleus							
9654	<i>TLL4</i>	1125.89	0.11	0.02	5.59	2.33*10 <sup>-8</sup>	0.0005
2624	<i>GATA2</i>	51.17	-0.27	0.05	-4.92	8.58*10 <sup>-7</sup>	0.0091
25904	<i>CNOT10</i>	695.68	0.06	0.01	4.84	1.27*10 <sup>-6</sup>	0.0091
222256	<i>CDHR3</i>	1483.68	0.19	0.04	4.75	1.99*10 <sup>-6</sup>	0.0106
375611	<i>SLC26A5</i>	63.80	0.28	0.06	4.62	3.81*10 <sup>-6</sup>	0.0163
Putamen							
1674	<i>DES</i>	22.06	-0.86	0.18	-4.70	2.64*10 <sup>-6</sup>	0.0486
2050	<i>EPHB4</i>	118.04	-0.19	0.05	-4.19	2.78*10 <sup>-5</sup>	0.0939
9144	<i>SYNGR2</i>	499.84	-0.20	0.05	-4.19	2.76*10 <sup>-5</sup>	0.0939
55741	<i>EDEM2</i>	348.56	-0.07	0.02	-4.23	2.30*10 <sup>-5</sup>	0.0939
84245	<i>MRI1</i>	662.19	-0.13	0.03	-4.13	3.57*10 <sup>-5</sup>	0.0939
Ventral Striatum							
81570	<i>CLPB</i>	1188.85	-0.11	0.02	-4.56	5.16*10 <sup>-6</sup>	0.0653
22899	<i>ARHGEF15</i>	54.23	-0.26	0.06	-4.49	7.04*10 <sup>-6</sup>	0.0653
55584	<i>CHRNA9</i>	5.58	-1.17	0.26	-4.44	9.14*10 <sup>-6</sup>	0.0653
100463488	<i>MTRNR2L10</i>	4.91	-2.07	0.50	-4.16	3.23*10 <sup>-5</sup>	0.1730
389161	<i>ANKUB1</i>	30.26	1.35	0.34	4.02	5.79*10 <sup>-5</sup>	0.2480

*Top 5 differentially expressed genes in caudate nucleus, putamen and ventral striatum.*





